恩他卡朋添加治疗帕金森病症状波动的系统评价  

Entacapone for motor fluctuations in Parkinson＇s disease： a systematic review

作　　者：周明珠[1] 陈伟[1] 刘振国[1] 干静[1] 

机构地区：[1]上海交通大学医学院附属新华医院神经科,200092

出　　处：《中华神经科杂志》2008年第8期514-519,共6页Chinese Journal of Neurology

基　　金：基金项目：国家教育部留学回国人员基金资助项目（2006-331）;上海市教委发展基金资助项目（06BZ048）;上海市浦江人才计划资助项目

摘　　要：目的系统评价恩他卡朋治疗帕金森病（PD）症状波动的疗效。方法采用Pubmed、Embase、Cochrane Database及其他互联网公共搜索引擎作为检索工具，检索国内外1966-2007年6月已发表的有关恩他卡朋对照、安慰剂治疗PD症状波动的临床研究资料。由2位研究者独立评价研究质量。使用Revman4．2．10进行统计学处理。结果共纳入10项随机对照临床试验（RCT）研究（共2212例患者），结果表明恩他卡朋治疗PD伴症状波动的患者有延长“开”期、缩短“关”期、减少每日左旋多巴剂量（IVMD=-1．41，95％CI-2．09～-0．72）和改善“开”期运动症状及生活质量的趋势，然而与安慰剂比，恩他卡朋可以增加异动症的发生率（OR=2．00，95％CI1．55—2．58）。结论恩他卡朋可以改善PD症状波动，同时也需要更多设有相同判效指标的大样本高质量RCT研究进一步证实。Objective To study the efficacy of entacapone for motor fluctuations in Parkinson＇ s disease. Methods Pubmed, Embase, Cochrane Database were searched for randomized controlled trial studies （RCTs） on entacapone compared to placebo in the treatment of Parkinson＇ s disease with motor fluctuations. Data were extracted and evaluated by two reviewers independently with designed extraction form. Revman 4. 2. 10 software was used for data analysis. Results Ten RCTs involving 2212 patients were included. The results showed that entacapone tends to increase ＂on＂ time, decrease ＂off＂ time and daily levodopa dosage （ WMD = - 1.41,95% CI -2. 09- -0. 72） and improve ＂on＂ time motor symptoms and the quality of life. But it might increase the rate of dyskinesia（OR = 2.00, 95% CI 1.55-2.58）. Conclusion The systematic review indicates that entacapone might be an effective agent for parkinsenian patients with motor fluctuations and more high quality RCTs with the same effect measures are required.

关 键 词：帕金森病 儿茶酚类 儿茶酚O-甲基转移酶 随机对照试验 评价研究 

分 类 号：R686[医药卫生—骨科学]